TL;DR
Researchers have developed and validated a new, highly sensitive, and fully automated assay for Neurofilament Light Chain (NfL), a critical biomarker for nerve cell damage. By porting this assay to widely available clinical platforms (Siemens ADVIA Centaur and Atellica), they have bridged the gap between specialized research tools and the high-throughput requirements of global clinical practice and drug development.
What Problem Does This Paper Address?
Neurofilament Light Chain (NfL) is a protein released into the cerebrospinal fluid (CSF) and blood whenever axons—the "wiring" of the nervous system—are damaged. This makes it an invaluable biomarker for tracking diseases like Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS).
However, NfL concentrations in the blood are incredibly low (often in the picogram per milliliter range). Until recently, measuring these levels required specialized "research-use-only" platforms like Simoa, which are not always available in standard clinical laboratories. To use NfL for routine clinical decision-making or large-scale global drug trials, the medical community needs an assay that is standardized, extremely sensitive, and compatible with the automated "workhorse" analyzers already found in hospitals worldwide.
Methods
The authors developed an immunometric (sandwich) assay that uses:
- Capture & Detection: Two specific antibodies (originally from Uman Diagnostics) that bind to NfL.
- Technology: Paramagnetic particle-based capture and acridinium ester (AE) chemiluminometric detection.
- Automation: The assay was first prototyped on the ADVIA Centaur XP and then optimized for the Atellica IM system.
- Validation: The team followed rigorous Clinical and Laboratory Standards Institute (CLSI) protocols to test sensitivity, precision, linearity, and potential interference from substances like biotin or hemoglobin.
Datasets
The study utilized several types of samples for validation:
- Analytical Samples: Human serum and plasma pools (K2 EDTA and lithium heparin) and CSF samples from commercial sources.
- Clinical MS Samples: 458 serum samples from patients enrolled in the MSPATHS biorepository and the ADVANCE clinical trial.
- Clinical ALS Samples: CSF samples from healthy controls and patients with a confirmed ALS diagnosis.
Key Insights and Ideas
- Bridging the Gap: The most significant "aha moment" is that this automated clinical platform achieves a Lower Limit of Quantitation (LLoQ) of 1.85 pg/mL. This matches the sensitivity required to detect subtle neuronal injury in blood samples, a feat previously reserved for specialized research platforms.
- Strong Correlation: The assay showed a high correlation ($R^2 = 0.907$) with the Quanterix Simoa platform. This is crucial because it suggests that the wealth of existing research data generated on Simoa can be meaningfully translated to results from this new clinical assay.
- Clinical Predictive Power: In MS patients, the study found that baseline blood NfL levels measured with this assay could predict the development of new brain lesions (seen on MRI) six months later. This confirms the assay's utility as a "look-ahead" tool for disease activity.
Key Results
- Sensitivity: LLoQ of 1.85 pg/mL for serum and a reportable range up to 500 pg/mL (and much higher for CSF).
- Precision: Within-laboratory precision (CV) was <6%, indicating high repeatability.
- Speed & Throughput: The Atellica IM system can process up to 171 tests per hour, with the first result available in just 51 minutes.
- Specificity: Extremely low cross-reactivity (<0.7%) with related proteins (Neurofilament Medium and Heavy chains), ensuring the assay specifically measures NfL.
- Clinical Differentiation: The assay clearly distinguished ALS patients from healthy controls, with CSF NfL levels in ALS patients being roughly two orders of magnitude higher than those in serum.
Limitations and Future Work
- LDT Status: Currently, this assay is implemented as a Laboratory Developed Test (LDT) at Siemens’ CLIA laboratory rather than a cleared "In Vitro Diagnostic" (IVD) kit that any lab can purchase and run independently.
- Interference: The authors noted that high levels of hemoglobin (from ruptured red blood cells, or hemolysis) can interfere with results, meaning sample quality remains a critical factor.
- Reference Ranges: While the assay is technically sound, the authors emphasize the need for larger studies to establish "normative reference populations"—essentially defining what a "normal" NfL level looks like across different age groups and sexes to better interpret clinical results.
Summary updated